Finance
Novonesis to buy DSM-Firmenich's stake in enzymes venture for $1.6 billion
Published by Global Banking & Finance Review®
Posted on February 11, 2025
1 min readLast updated: January 26, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on February 11, 2025
1 min readLast updated: January 26, 2026
Novonesis will acquire DSM-Firmenich's stake in their enzymes venture for $1.6 billion, dissolving the Feed Enzyme Alliance and expanding its biosolutions value chain.
COPENHAGEN (Reuters) -Novonesis said on Tuesday that it had agreed to buy the stake of its partner, Swiss-Dutch chemical manufacturer DSM-Firmenich, in their joint enzymes venture for 1.5 billion euros ($1.55 billion).
The Danish company, created from the merger of food ingredients and enzymes makers Novozymes and Chr. Hansen, said the so-called Feed Enzyme Alliance would be dissolved and Novonesis would take over its sales and distribution activities.
"Growing global protein demand, coupled with increasing land and water scarcity, requires innovative solutions," Novonesis CEO Ester Baiget said in a statement.
"Now with an expanded presence across the animal biosolutions value chain, we are better positioned to create more value for customers with sustainable value adding biosolutions".
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
The main topic is Novonesis acquiring DSM-Firmenich's stake in their joint enzymes venture for $1.6 billion.
Novonesis aims to enhance its presence in the animal biosolutions value chain and address global protein demand.
The Feed Enzyme Alliance will be dissolved as Novonesis takes over sales and distribution activities.
Explore more articles in the Finance category
